Navigation Links
Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2009
Date:7/14/2009

of the Securities Act. This stock sale involved no discounts or warrants and required only a modest commission be paid to the underwriter.

Paul Lytle, chief financial officer of Peregrine, noted, "Our 'At the Market' sales agreement has proven to be a very successful financing vehicle, allowing us to sell shares of common stock at market prices and to raise the full target amount of $7.5 million in new equity for the company at favorable terms. With the successful closing of this equity sale, Peregrine had met all the conditions to draw down the second $5 million tranche under our current loan agreement. However, we have opted not to draw down the additional debt at this time. Instead, we plan to rely on our other potential sources of capital and the projected revenues from Avid and our DTRA government contract, thereby avoiding the additional costs and future repayment of principal and interest associated with taking on additional debt. The original loan we closed last December has served its purpose by allowing us to continue our R&D programs during very tough economic conditions."

The company's FY 2009 Annual Report on Form 10-K to be filed today will include an audit opinion with a "going concern" qualification. The qualification is a statement in the audit opinion of Ernst & Young LLP, the company's independent registered public accounting firm, expressing substantial doubt, based upon Peregrine's current financial resources, as to whether the company can continue to meet its financial obligations beyond fiscal year 2010 without access to additional cash and cash equivalents. Nasdaq Marketplace Rule 4350(b) (1) (B) requires Nasdaq-listed companies to announce publicly through the news media the receipt of an audit opinion containing a "going concern" qualification.

Mr. Lytle added, "We believe Peregrine has sufficient financial resources to meet its obligations through at least FY 2
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related medicine news :

1. Positive Results From Peregrine Pharmaceuticals Bavituximab Phase l HCV Trial Presented at AASLD Meeting
2. Peregrine Pharmaceuticals Receives Approval to Begin New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
3. Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials
4. Data Published in Nature Medicine Highlights Ability of Peregrine Pharmaceuticals Bavituximab to Cure Lethal Virus Infections
5. Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies
6. Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009
7. Peregrine Pharmaceuticals Bavituximab Achieves Primary Endpoint in First Stage of Phase II Breast Cancer Study
8. Peregrine Pharmaceuticals to Report Third Quarter FY 2009 Financial Results
9. Peregrine Pharmaceuticals Receives Additional Time to Regain Compliance With NASDAQs Minimum Bid Price Rule
10. Peregrine Pharmaceuticals Reports Progress in Cotara(R) Brain Cancer Clinical Program
11. ASCO Research Foundation Grant Will Support Study of Peregrines Bavituximab in Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... Fla. (PRWEB) May 05, 2015 Baptist ... the Commission on Cancer (CoC) of the American College ... cancer program must meet more than 30 Commission on ... through a survey process, and maintain levels of excellence ... , When patients choose to seek care locally at ...
(Date:5/5/2015)... Atlanta, Georgia (PRWEB) May 05, 2015 ... Software of Victoria BC announced the Skedans Sensor ... The platform, for mobile and web app developers, provides ... from airborne and mobile sensors. , The Skedans Sensor ... at the intersection of the Internet of Things, Web ...
(Date:5/5/2015)... May 05, 2015 MAP Health Management, ... revenue cycle management for addiction treatment facilities, announced today ... President of Business Development. Mr. Mooney, who has more ... field, will be responsible for developing new strategic partnerships ... MAP’s core products and new initiatives. , Prior to ...
(Date:5/5/2015)... (PRWEB) May 05, 2015 Okyanos, the ... Lifestyle Report today. The study was conducted to determine ... as osteoarthritis and sports-related injuries have had ... stiffness was the most prevalent symptom reported at 73%, ... as walking, standing and bending over. Over half of ...
(Date:5/5/2015)... On April 8th, 2015, at the ... Recovery sponsored Durkin Entertainment’s “RockNRolla” EcoLuxe Lounge, a daylong ... sustainable product placement in TV and film. , ... of ecologically sound and socially conscious products and services, ... that makes appearances at various awards ceremonies and festivals ...
Breaking Medicine News(10 mins):Health News:Baptist Medical Center Jacksonville Receives National Cancer Reaccreditation 2Health News:Baptist Medical Center Jacksonville Receives National Cancer Reaccreditation 3Health News:Baptist Medical Center Jacksonville Receives National Cancer Reaccreditation 4Health News:Skedans Systems Announces Skedans Sensor Collaboration Platform at AUVSI's Unmanned Systems 2015 in Atlanta 2Health News:Jimmy Mooney, an Addiction Treatment Veteran, Named Vice President of Business Development at MAP Health Management, LLC 2Health News:Okyanos Study Finds Orthopedic Patients Plagued with Pain 2Health News:Okyanos Study Finds Orthopedic Patients Plagued with Pain 3Health News:Choices Recovery Mishawaka Talks About Overcoming Adversity with Actor Matthew Ziff at the “RockNRolla Movie Awards” EcoLuxe Lounge 2
... , , BANNOCKBURN, Ill., July 14 ... are afoot. The season is also notoriously a time when people want ... daunting, especially with so many people pressed for time and money. ... summer that,s accessible, affordable and can accommodate even the busiest of schedules ...
... , , , ... (NYSE: WPI ), a leading specialty pharmaceutical company, ... the U.S. Food and Drug Administration (FDA) on its New ... injectable suspension), a 24-week formulation of TRELSTAR(R) for the palliative ...
... ... services to hospital , ... TX (Vocus) July 14, 2009 -- Broadlane announced today that Temple University Health ... chain management and procurement services in a three-year exclusive agreement to help manage its ...
... , , , NEW YORK, ... beat its original goal for first time fundraising event -- the Hudson Valley ... To date, it has raised more than $280,000. The objective has ... According to Anthony Mann, founder of the bike ride and President-Elect of ...
... SHANGHAI, July 14 Fi Asia-China, China,s premiere event for professionals ... China on 23-25 June, 2009. Building on the successful launch of ... shows ran alongside Fi Asia-China and proved to be the major draw ... , Ingredients for Healthy Living , ...
... , DEERFIELD BEACH, Fla., July 14 A ... suggests drinking fat-free milk in the morning may be better than drinking ... However, the study only looks at feeling full, not weight loss ... are intolerant to proteins in milk, or lactose intolerant, which can cause ...
Cached Medicine News:Health News:Looking to Shape Up for Summer? The Solution May Be the Steps You're Already Taking 2Health News:Looking to Shape Up for Summer? The Solution May Be the Steps You're Already Taking 3Health News:Watson Pharmaceuticals Receives a Complete Response Letter for Its 24-Week Formulation of TRELSTAR(R) (triptorelin pamoate) NDA from US FDA 2Health News:Watson Pharmaceuticals Receives a Complete Response Letter for Its 24-Week Formulation of TRELSTAR(R) (triptorelin pamoate) NDA from US FDA 3Health News:Temple University Health System to Improve Supply Chain with Broadlane 2Health News:Temple University Health System to Improve Supply Chain with Broadlane 3Health News:Temple University Health System to Improve Supply Chain with Broadlane 4Health News:Temple University Health System to Improve Supply Chain with Broadlane 5Health News:Temple University Health System to Improve Supply Chain with Broadlane 6Health News:JBFCS Surpasses Fundraising Goal For Hudson Valley Bike Ride Despite Difficult Financial Times 2Health News:The Power of Functional Foods is the Key to Fi Asia-China's Success 2Health News:The Power of Functional Foods is the Key to Fi Asia-China's Success 3Health News:Milk: Does It Do A Body Good? 2Health News:Milk: Does It Do A Body Good? 3
(Date:5/5/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/74vlb2/electro_surgical ) ... Surgical Market" report to their offering. ... achieve a CAGR of 7% for the forecast ... patients as well as surgeons such as fast ... bleeding control and improved accuracy are some of ...
(Date:5/5/2015)... Calif. and ST. LOUIS ... high blood pressure or high cholesterol may achieve better ... performance-based networks, according to early results of a unique ... (NASDAQ: ESRX ). "Pharmacists are one ... their frequent interactions with our members presents enormous opportunities ...
(Date:5/5/2015)... May 5, 2015 Big Market Research presents ... Europe , ( France , ... Spain , UK) and Japan . Current ... The report provides the 5-year test volume and sales forecasts by ... Anti-HBc, Anti-HBs, Anti-HAV, Hepatitis Delta, HBc Ag, HBe Ag, and ALT/SGPT ...
Breaking Medicine Technology:Global Electro Surgical Market 2015 2SCAN Health Plan, Express Scripts' Quality Network Improves Medicare Beneficiary Health 2SCAN Health Plan, Express Scripts' Quality Network Improves Medicare Beneficiary Health 3SCAN Health Plan, Express Scripts' Quality Network Improves Medicare Beneficiary Health 42015 Opportunities in the Global Hepatitis Diagnostic Testing Market: Big Market Research 22015 Opportunities in the Global Hepatitis Diagnostic Testing Market: Big Market Research 3
Superior Skin Care...FlexWear skin barrier provides skin protection for an extended wear time....
Protects skin from corrosive drainage with the standard wear, FlexWear skin barrier. Convenient: accommodates stomas up to 102 mm; wide bottom opening permits hand access; attached pouch closure....
FlexWear is a cross-linked hydrocolloid skin barrier that provides aggressive adherence and is designed for more than one day weartime....
Inquire...
Medicine Products: